Advertisement

Topics

Cambridge Antibody Technology Group plc Company Profile

16:25 EDT 21st September 2018 | BioPortfolio

The foundation of CAT's business is its unique antibody technologies, which it continues to develop and exploit. Based on this, CAT has established a position as a world leader, exploiting the characteristics of antibodies both to discover and validate new disease targets and to develop human monoclonal antibodies as new treatments for disease.

Location

The Science Park
Melbourn
Cambridgeshire
SG8 6JJ
United Kingdom

Contact

Phone: +44 (0) 1763 263 233
Fax: +44 (0) 1763 263 413
Email: info@cambridgeantibody.com


News Articles [1924 Associated News Articles listed on BioPortfolio]

#jobs #lifescience CK Group: Scientific & Project Manager – Cambridge

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: CK Group: Scientific & Project Manager – Cambridge . Up to £24.65...

#jobs #lifescience CK Group: Medical Information Contractor – Cambridge

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: CK Group: Medical Information Contractor – Cambridge . Very competitive...

New Rabbit Monclonal Antibody to Group B Streptococcus

New antibody reacts with the GBS Lancefield carbohydrate antigen found on the surface of the bacterium

Could a new antibody screening method lead to better drugs?

Antibody proteins have been the fastest-growing class of approved drugs over the last two decades, but current antibody drug discovery...Read More... The post Could a new antibody screening method lea...

Cambridge Analytica Suspends CEO After Alarming Reports On Its Election Maneuvers

Cambridge Analytica, the British political research group linked to President

IONTAS Celebrates 5 Years of Antibody Discovery

Attributes ongoing success to scientific ethos, project management, and innovative research programs IONTAS Limited (IONTAS), a leader in the discovery and optimisation of ...

Cambridge Enterprise: How Apollo Therapeutics is driving forward therapeutic innovation.

Iain Thomas, Head of Life Sciences at Cambridge University’s technology transfer arm, discusses the recent launch of Apollo Therapeutics, an ambitious collaboration between AstraZeneca, GlaxoSmithK...

Cambridge Consultants, Exact Imaging to apply AI technology to detect prostate cancer

Cambridge Consultants is applying deep learning to high-resolution micro-ultrasound imaging to detect suspicious regions of tissue, enabling urologists to use additional data in their biopsy protocol....

PubMed Articles [3713 Associated PubMed Articles listed on BioPortfolio]

The Cambridge Social History of Modern Ireland : Edited by E.F. Biagini and M.E. Daly, Cambridge, United Kingdom and New York, NY: Cambridge University Press, 2017.

Preventive effect of tumor necrosis factor inhibitors versus nonsteroidal anti-inflammatory drugs on uveitis in patients with ankylosing spondylitis.

To compare the preventive effect of tumor necrosis factor (TNF) inhibitors (anti-TNF antibody and soluble TNF receptor fusion protein (TNFR)) and nonsteroidal anti-inflammatory drugs (NSAIDs) on uveit...

Measuring Antibody-Antigen Binding Kinetics Using Surface Plasmon Resonance.

Surface plasmon resonance (SPR) is now widely embraced as a technology for monitoring a diverse range of protein-protein interactions and is considered almost de rigueur for characterizing antibody-an...

Computing threshold antibody levels of protection in vaccine clinical trials: An assessment of methodological bias.

In the development of new vaccines, understanding the level of vaccine-induced antibody that is sufficient to protect against disease can simplify and expedite the development and licensing process. I...

Siglec-6 on chronic lymphocytic leukemia cells is a target for post-allogeneic hematopoietic stem cell transplantation antibodies.

Although the five-year survival rate of chronic lymphocytic leukemia (CLL) patients has risen to >80%, the only potentially curative treatment is allogeneic hematopoietic stem cell transplantation ...

Clinical Trials [7072 Associated Clinical Trials listed on BioPortfolio]

Weight Loss for Obese Individuals With Gout

This study evaluates effect of weight loss in a group of obese patients with gouty arthritis. The study is a randomised group trial where half the patients receive intensive weight loss in...

Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response

In adult kidney transplant recipients a therapy-responder and non-responder phenotype by antibody mediated rejection will be precisely defined according to clinical and histological charac...

App-technology to Improve Healthy Lifestyle Behaviors Among Working Adults

The aim of this study is to evaluate if modern technology such as smartphone applications can be used to facilitate lifestyle changes and thereby improve health-related quality of life in ...

Feasibility Study Identifying Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Young Infants.

Feasibility phase for a study to evaluate antibody levels against Group B Streptococcus in mothers and their infants at delivery to establish antibody levels associated with reductions in ...

A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine

This study looks at the body's immune responses to a GBS vaccine 2 years after the orginal vaccine(s) were given in the V98P1 study. Blood will be drawn and evaluated for GBS antibody lev...

Companies [3168 Associated Companies listed on BioPortfolio]

Cambridge Antibody Technology

Cambridge Antibody Technology (CAT) is a biopharmaceutical company committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives.CAT has strong ...

Cambridge Antibody Technology Group plc

The foundation of CAT's business is its unique antibody technologies, which it continues to develop and exploit. Based on this, CAT has established a position as a world leader, exploiting the charact...

Domantis Inc

Domantis Limited was launched in December 2000 by Sir Gregory Winter and Dr Ian Tomlinson of the MRC–LMB with the backing of the MRC and MVM Limited to commercialise Domain Antibody products. To dat...

Granta Park Ltd

Granta Park has established itself as the leading research park in the Cambridge sub-region. Concentrating on the life sciences it has attracted many of the foremost businesses in the field, including...

The Cambridge Group

The Cambridge Group (http://www.thecambridgegroup.com) is a strategy consulting firm focused on the development of growth strategies for Fortune 500 companies. For over 30 years, The Cambridge Gr...

More Information about "Cambridge Antibody Technology Group plc" on BioPortfolio

We have published hundreds of Cambridge Antibody Technology Group plc news stories on BioPortfolio along with dozens of Cambridge Antibody Technology Group plc Clinical Trials and PubMed Articles about Cambridge Antibody Technology Group plc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cambridge Antibody Technology Group plc Companies in our database. You can also find out about relevant Cambridge Antibody Technology Group plc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record